We provide you with 20 years of free, institutional-grade data for DYN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DYN. Explore the full financial landscape of DYN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about DYN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Dyne Therapeutics, Inc(NASDAQ:DYN) 
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral ...
Website: http://www.dyne-tx.com
Founded: 2017
Full Time Employees: 36
CEO: Joshua T. Brumm
Sector: Other
Industry: Other
Share this website to your friends